Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

Introduction : Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much l...

全面介紹

書目詳細資料

發表在:	Gastroenterology Review
Main Authors:	Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
格式:	Article
語言:	英语
出版:	Termedia Publishing House 2016-12-01
主題:	adalimumab deep remission mucosal healing Crohn’s disease
在線閱讀:	https://www.termedia.pl/Adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-Crohn-s-disease,41,28947,1,1.html